Extracellular matrix materials are commercially available and are used in reconstructive surgery, treatment of chronic wounds, and some orthopedic surgeries; as of January 2017 clinical studies were under way to use them in heart surgery to try to repair damaged heart tissue.
The use of fish skin with its natural constituent of omega 3, has been developed by an Icelandic company Kereceis. Omega 3 is a natural anti-inflammatory, and the fish skin material acts as a scaffold for cell regeneration. In 2016 their product Omega3 Wound was approved by the FDA for the treatment of chronic wounds and burns. In 2021 the FDA gave approval for Omega3 Surgibind to be used in surgical applications including plastic surgery.